Supplementary Tables 1-3 from A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), As Monotherapy and in Combination with Erlotinib in Advanced Cancer
openalex(2023)
关键词
Cancer Metabolism
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要